Impact of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: Landmark analysis of 10 year data from first-line clinical trials

被引：0
|
作者：
Bolt, T. A. [1 ]
Pauligk, C. [1 ]
Werner, D. [1 ]
Mayer, F. [2 ]
Hofheinz, R. [3 ]
Nils, H. [4 ]
Luley, K. [5 ]
Schmalenberg, H. [6 ]
Egger, M. [7 ]
Al-Batran, S-E. [1 ]
机构：
[1] Krankenhaus Norwest, Inst Klin Onkol Forsch, Frankfurt, Germany
[2] Univ Med Ctr, Tubingen, Germany
[3] Univ Med Ctr, Dept Hematol & Med Oncol, Mannheim, Germany
[4] Klinikum Wolfsburg, Wolfsburg, Germany
[5] Univ Klinikum Lubeck, Lubeck, Germany
[6] Univ Tumorctr Jena, Jena, Germany
[7] Ortenau Klinikum, Lahr Ettenheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [1] Impact of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: Landmark analysis of 10-year data from first-line clinical trials
    Bolt, Toki Anna
    Pauligk, Claudia
    Werner, Dominique
    Hofheinz, Ralf Dieter
    Mayer, Frank
    Luley, Kim Barbara
    Homann, Nils
    Schmalenberg, Harald
    Egger, Matthias
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] The association of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: A pooled analysis of individual patient data from first-line clinical trials
    Bolt, T. A.
    Pauligk, C.
    Werner, D.
    Mayer, F.
    Hofheinz, R. D.
    Homann, N.
    Luley, K.
    Al-Batran, S. -E
    ONKOLOGIE, 2013, 36 : 122 - 123
  • [3] The association of objective response and overall survival in patients with inoperable or metastatic gastric and esophagogastric junction (EGJ) cancer: A pooled analysis of individual patient data from first-line clinical trials.
    Bolt, Toki Anna
    Pauligk, Claudia
    Werner, Dominique
    Mayer, Frank
    Hofheinz, Ralf Dieter
    Homann, Nils
    Luley, Kim
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period
    Matikas, Alexios
    Kotsakis, Athanasios
    Perraki, Maria
    Hatzidaki, Dora
    Kalbakis, Konstantinos
    Kontopodis, Emmanouil
    Nikolaou, Michail
    Georgoulias, Vasilios
    BREAST CARE, 2022, 17 (03) : 264 - 271
  • [5] Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
    Suzuki, Chikako
    Blomqvist, Lennart
    Hatschek, Thomas
    Carlsson, Lena
    Einbeigi, Zakaria
    Linderholm, Barbro
    Lindh, Birgitta
    Loman, Niklas
    Malmberg, Martin
    Rotstein, Samuel
    Soderberg, Martin
    Sundqvist, Marie
    Walz, Thomas M.
    Astrom, Gunnar
    Fujii, Hirofumi
    Jacobsson, Hans
    Glimelius, Bengt
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [6] Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
    Chikako Suzuki
    Lennart Blomqvist
    Thomas Hatschek
    Lena Carlsson
    Zakaria Einbeigi
    Barbro Linderholm
    Birgitta Lindh
    Niklas Loman
    Martin Malmberg
    Samuel Rotstein
    Martin Söderberg
    Marie Sundqvist
    Thomas M. Walz
    Gunnar Åström
    Hirofumi Fujii
    Hans Jacobsson
    Bengt Glimelius
    Medical Oncology, 2013, 30
  • [7] Objective response of first-line chemotherapy in patients with metastatic triple-negative breast cancer confers a better overall survival.
    Li, Ting
    Zhang, Jian
    Wang, Zhonghua
    Wang, Biyun
    Zhang, Sheng
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Xie, Jie
    Zhang, JinFeng
    Hu, Xi-Chun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)
    O'Shaughnessy, J.
    Miles, D.
    Gray, R. J.
    Dieras, V.
    Perez, E. A.
    Zon, R.
    Cortes, J.
    Zhou, X.
    Phan, S.
    Miller, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab
    Kato, Minoru
    Kobayashi, Takashi
    Matsui, Yoshiyuki
    Ito, Katsuhiro
    Hikami, Kensuke
    Yamada, Takeshi
    Ogawa, Kosuke
    Nakamura, Kenji
    Sassa, Naoto
    Yokomizo, Akira
    Abe, Takashige
    Tsuchihashi, Kazunari
    Tatarano, Shuichi
    Inokuchi, Junichi
    Tomida, Ryotaro
    Fujiwara, Maki
    Takahashi, Atsushi
    Matsumoto, Kazumasa
    Shimizu, Kosuke
    Araki, Hiromasa
    Kurahashi, Ryoma
    Ozaki, Yu
    Tashiro, Yu
    Uegaki, Masayuki
    Kojima, Takahiro
    Uchida, Junji
    Ogawa, Osamu
    Nishiyama, Hiroyuki
    Kitamura, Hiroshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (12) : 1261 - 1267
  • [10] The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials
    Lima Pereira, Allan Andresson
    De Mendonca Rego, Juliana Florinda
    Munhoz, Rodrigo Ramela
    Hoff, Paulo Marcelo
    Sasse, Andre Deeke
    Riechelmann, Rachel P.
    ACTA ONCOLOGICA, 2015, 54 (10) : 1737 - 1746
12345